top of page

JAK2 V617F Mutation
Detection RT-PCR Kit

JAK2 V617F Mutation Detection Kit is a Real-time PCR in vitro diagnostic kit for the detection of the JAK2 (Janus Kinase 2) V617F allele in genomic DNA extracted from EDTA whole blood against a background of wild-type genomic DNA. The mutation observed is a Guanine to Thymidine transversion in position 1849 of the JAK2 gene, which leads to valine to phenylalanine substitution in position 617 of the protein.

SKU

  • 100 Rxns : NDXIVD004

  • 50 Rxns : NDXIVD004_01

  • 20 Rxns : NDXIVD004_02

JAK2 V617F Mutation Detection Kit.png

CDSCO Approved

Features & Benefits: 
  • Kit Format & Chemistry: Single-Tube, Multiplex Real-Time PCR Assay based on Taqman-probe-based Chemistry

  • Target: LNA-based for detection of JAK2 (Janus Kinase 2) V617F allele in genomic DNA against a background of Wild Type Allele. 

  • Internal Control: Beta Actin

  • LoD /Analytical sensitivity: 10 copies/uL

  • PCR Run time: <90 Minutes

  • Sample Compatibility: DNA extracted from Whole Blood EDTA.  

  • RT-PCR: Open-System Platform; Instruments with FAM, Texas Red/ROX Channels

  • Standardized: WHO International standards - NIBSC 16/120

Storage & Precautions

  • Recommended Storage: -20°C

  • For Professional Use only.

  • Read user manual

Clinical Relevance

JAK2 V617F is a somatic point mutation in the Janus Kinase 2 gene that results in constitutive activation of the JAK-STAT signaling pathway, independent of normal regulatory control. This uncontrolled signaling promotes excessive proliferation and survival of myeloid lineage cells, leading to the development of myeloproliferative neoplasms (MPNs). The JAK2 V617F mutation is the most common genetic abnormality in MPNs and is detected in approximately 95% of patients with Polycythemia Vera (PV) and in 50–60% of patients with Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). Detection of the JAK2 V617F mutation serves as a critical diagnostic and classification marker for MPNs, helps differentiate clonal myeloproliferation from reactive conditions, and supports disease diagnosis, prognosis, and therapeutic decision-making.

Get in Quote

 1800 202 3252

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page